Ad
related to: her2 gastric cancer treatment- Dosing and Admin
View Recommended Dosing and
Administration Information.
- Biomarker Testing
See How Testing Reveals a Prevalent
Target for First-Line Treatment.
- Efficacy & Safety
View Response Data, Study Design,
& Safety Data for Phase 3 Trials.
- Request a Rep
Request a Representative to Learn
More About This Treatment Option.
- Dosing and Admin
Search results
Results from the WOW.Com Content Network
Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [30] [27] [31] [32] It is specifically used for cancer that is HER2 receptor positive. [30] It may be used by itself or together with other chemotherapy medication. [30]
Over-expression is also known to occur in ovarian, [19] stomach, adenocarcinoma of the lung [20] and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma, [21] [22] e.g. HER2 is over-expressed in approximately 7-34% of patients with gastric cancer [23] [24] and in 30% of salivary duct carcinomas.
For instance, some stomach cancers express a gene called HER2, which is also linked to breast cancer. “The drugs that work in HER2 breast cancer to some degree work in HER2 gastric cancer.
In the United States, trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.
In China, disitamab vedotin was approved in 2021 for the treatment of patients with HER2-overexpressing locally advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma, who have received at least two systemic chemotherapy regimens. [2]
It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. [2] Patritumab deruxtecan, an experimental antibody–drug conjugate to treat non-small-cell lung cancer. [3] [4] [5] Ifinatamab deruxtecan, an experimental anti-cancer treatment. [6] [7]
Cancer of the stomach is difficult to cure unless it is found at an early stage (before it has begun to spread). Unfortunately, because early stomach cancer causes few symptoms, the disease is usually advanced when the diagnosis is made. [80] Treatment for stomach cancer may include surgery, [81] chemotherapy, [13] or radiation therapy. [82]
Ad
related to: her2 gastric cancer treatment